Clinical trial
A Phase 1/2 Study Of CMC-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-Cell Non-Hodgkin's Lymphoma
The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin [CMC-544] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.
| Category | Value |
|---|---|
| Date last updated at source | 2015-10-06 |
| Study type(s) | Interventional |
| Expected enrolment | 119 |
| Study start date | 2006-05-01 |
| Estimated primary completion date | 2014-06-01 |